GleamWall
中文EN

SCNX Scienture Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1382574 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY127.4%
TTM net income YoY-96.3%
TTM EPS YoY144.2%
Revenue 3-yr CAGR-24.9%
Net income 3-yr CAGR—

Margins

Gross margin78.5%
Operating margin-2,788.5%
Net margin-2,715.9%
FCF margin—
EBITDA margin-2,662.9%

Returns

ROE-57.1%
ROA-47.1%
ROIC (approx.)-47.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets32.6%
Debt / equity0.00x
Current ratio1.10x
Interest coverage-25.26x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-30.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.25M$343,639$56,325-$168,699$590,050$0$10,258$53,083
Cost of revenue$234,628$7,860$2,475$75,113$15,429$0$9,585$50,258
Gross profit$1.02M$335,779$53,850-$243,812$574,621$0$673$2,825
R&D expense$1.39M$1.17M$793,984$368,698$169,344$843,549$574,679$982,707
SG&A expense$2.93M$368,790$1.07M$1.48M$2.17M$2.93M$1.36M$1.39M
Operating income-$5.72M-$2.70M-$3.51M-$29.50M-$4.36M-$5.16M-$3.57M-$4.21M
Interest expense$377,947$269,785$37,019$955,499$1.80M$653,493$670,784$1.01M
Pretax income———-$30.12M-$3.61M-$6.72M-$3.06M-$7.34M
Net income-$6.01M-$2.82M-$3.40M-$28.12M-$3.61M-$6.72M-$3.06M-$7.16M
EBITDA-$5.26M-$2.24M-$3.06M-$29.01M-$4.36M-$5.16M-$3.57M-$4.21M
EPS (basic)-3.76-0.07-0.08—-4.76-0.48-0.33—
EPS (diluted)-3.76-0.07-0.08—-4.76-0.48-0.33—
Weighted avg. shares (diluted)1.60M39.62M40.63M—758,30614.14M9.43M—
Banking
Deposits—$2.21M—$1.18M————
Balance sheet
Cash & equivalents$4.75M$8.19M$3.54M$6.66M$355,692$15,391$2.05M$308,096
Receivables$2.22M$385,313$722,545$731,328$590,050—$3,734$11,106
Inventory$998,109$203,074$210,934$213,408$234,521———
Current assets$8.83M$9.20M$4.77M$7.92M$1.42M$856,625$7.83M$6.31M
PP&E, net$14,500$14,500$15,000$15,500$16,000$16,500$17,000$17,500
Goodwill————$21.37M$21.37M$21.37M$21.37M
Intangibles$69.61M$70.07M$70.52M$70.97M$76.40M$76.40M$76.40M$76.40M
Total assets$87.18M$87.73M$80.66M$84.18M$84.18M$84.18M$84.18M$104.85M
Current liabilities$8.06M$3.03M$2.80M$2.74M$7.35M$7.69M$7.46M$7.91M
Long-term debt————$2.00M$3.58M$3.09M$2.90M
Total debt————$2.00M$3.58M$3.09M$2.90M
Total liabilities$28.44M$23.63M$13.84M$14.06M$22.16M$26.43M$25.20M$25.78M
Shareholders' equity$58.74M$64.10M$66.82M$70.12M$82.67M$77.86M$81.16M$79.07M
Net debt————$1.64M$3.56M$1.04M$2.59M
Shares outstanding1.79M41.06M40.63M1.63M23.13M16.13M12.52M8.75M
Cash flow statement
Operating cash flow-$3.46M-$3.13M-$2.92M-$5.18M-$3.21M-$2.03M-$2.96M-$2.91M
Capital expenditure———————$0
Free cash flow———————-$2.91M
Investing cash flow———————$0
Financing cash flow$39,562$10.79M-$200,000$11.48M$3.55M$0$4.70M$2.79M
Depreciation & amortization$460,167$461,571$454,346$490,281$500$500$500$0
Stock-based compensation$126,948$103,457$102,320$248,459$1.66M$162,437$437$437
Dividends paid———————$0

Free plan shows the latest 8 periods; Pro shows all 54 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.